Data Insights

ThisCART19A by Suzhou Fundamenta Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia. According...

Likelihood of Approval and Phase Transition Success Rate Model - ThisCART19A in Acquired (Autoimmune) Hemolytic Anemia

Data Insights

ThisCART19A by Suzhou Fundamenta Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - ThisCART19A in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

ThisCART19A by Suzhou Fundamenta Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - ThisCART19A in B-Cell Non-Hodgkin Lymphoma

Data Insights

ThisCART7 by Suzhou Fundamenta Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval

ThisCART7 is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData,...

Data Insights

ThisCART7 by Suzhou Fundamenta Therapeutics for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

ThisCART7 is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According...

Data Insights

Gene Therapy to Target CD22 for Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma by Suzhou Fundamenta Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

Gene Therapy to Target CD22 for Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma is under clinical development by Suzhou Fundamenta Therapeutics...

Data Insights

Gene-Modified Cell Therapy to Target CD7 for Oncology by Suzhou Fundamenta Therapeutics for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Gene-Modified Cell Therapy to Target CD7 for Oncology is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase...

Data Insights

ThisCART19A by Suzhou Fundamenta Therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL)....

Data Insights

ThisCART19A by Suzhou Fundamenta Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL)....